Exagen (NASDAQ: XGN) director reports 7,500 restricted stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

3/A

Rhea-AI Filing Summary

EXAGEN INC. director Chas McKhann filed an amended Form 3 reporting his equity holdings. The filing lists a direct position of 7,500 Restricted Stock Units as of July 17, 2025. The entry reflects a holding record only, with no explicit buy or sell transaction indicated.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McKhann Chas

Role null

Type	Security	Shares	Price	Value
holding	Restricted Stock Units	--	--	--

Holdings After Transaction: Restricted Stock Units — 7,500 shares (Direct, null)

Footnotes (1)

Key Figures

Restricted Stock Units held: 7,500 units

1 metrics

Restricted Stock Units held 7,500 units Total RSUs directly held after holding entry on July 17, 2025

Key Terms

Restricted Stock Units, Form 3/A, insider

3 terms

Restricted Stock Units financial

"The filing lists a direct position of 7,500 Restricted Stock Units as of July 17, 2025."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 3/A regulatory

"Chas McKhann filed an amended Form 3 reporting his equity holdings."

An amended Form 3 (Form 3/A) is a corrected or updated disclosure filed with regulators that revises an insider’s initial report of their ownership in a public company — typically for officers, directors or large shareholders. Investors use it like a corrected inventory list: it clarifies who owns how many shares and whether earlier reports had errors, helping assess insider confidence, possible conflicts and the accuracy of ownership records that can affect stock valuation and trust.

insider financial

"The filing reflects insider holdings by a director of Exagen."

Understanding Insider Trading Forms →

04/21/2026 - 08:00 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McKhann Chas

(Last)

(First)

(Middle)

5717 VERNON AVENUE S.

(Street)

EDINA

MINNESOTA

55436

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/17/2025

3. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/16/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	7,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Exagen (XGN) director Chas McKhann report in this Form 3/A?

The Form 3/A shows director Chas McKhann directly holds 7,500 Restricted Stock Units in Exagen. The holding is recorded as of July 17, 2025, and the entry is classified as a holding, with no explicit buy or sell transaction disclosed.

How many Restricted Stock Units does Chas McKhann hold in Exagen (XGN)?

Chas McKhann is reported as directly holding 7,500 Restricted Stock Units of Exagen. This figure is shown as the total number of units following the reported holding entry dated July 17, 2025 in the amended Form 3 filing.

Does the Exagen (XGN) Form 3/A show any insider buying or selling by Chas McKhann?

The Form 3/A does not identify any insider buying or selling activity for Chas McKhann. It classifies the entry as a holding record, listing 7,500 Restricted Stock Units as directly owned following the reported date of July 17, 2025.

What type of security is reported for Chas McKhann in Exagen (XGN)?

The filing reports McKhann’s position in Restricted Stock Units, rather than common shares or options. These units are shown as a direct holding, with a total of 7,500 units listed after the reported holding entry dated July 17, 2025.

Is Chas McKhann identified as an officer or just a director of Exagen (XGN)?

The amended Form 3 identifies Chas McKhann as a director of Exagen but not as an officer. The officer status is flagged as not applicable, while the director box is marked, aligning his role with board-level oversight rather than an executive management position.